Key result
Novel oral anticoagulants, including direct thrombin and factor Xa inhibitors, offer alternatives to vitamin K antagonists for thromboembolism prevention in cardiovascular disease.
This review summarizes the pharmacological properties and clinical evaluation of novel oral anticoagulants as alternatives to vitamin K antagonists for the prevention of thromboembolism in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Supports expanded anticoagulant choices in practice; extends Level 3 evidence but leaves open need for confirmatory trials.
Lip et al. (2010) conducted a review in Cardiovascular disease. Novel oral anticoagulants (e.g., dabigatran etexilate, rivaroxaban) vs. Vitamin K antagonists was evaluated. Novel oral anticoagulants, including direct thrombin and factor Xa inhibitors, offer alternatives to vitamin K antagonists for thromboembolism prevention in cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: